293 related articles for article (PubMed ID: 36077694)
41. Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.
Galland L; Roussot N; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Reda M; Albuisson J; Arnould L; Boidot R; Truntzer C; Ghiringhelli F; Ladoire S
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831640
[TBL] [Abstract][Full Text] [Related]
42. GSA: an independent development algorithm for calling copy number and detecting homologous recombination deficiency (HRD) from target capture sequencing.
Chen D; Shao M; Meng P; Wang C; Li Q; Cai Y; Song C; Wang X; Shi T
BMC Bioinformatics; 2021 Nov; 22(1):562. PubMed ID: 34814825
[TBL] [Abstract][Full Text] [Related]
43. Pan-cancer landscape of homologous recombination deficiency.
Nguyen L; W M Martens J; Van Hoeck A; Cuppen E
Nat Commun; 2020 Nov; 11(1):5584. PubMed ID: 33149131
[TBL] [Abstract][Full Text] [Related]
44. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract][Full Text] [Related]
45. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
[TBL] [Abstract][Full Text] [Related]
46. Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape.
Daly GR; Naidoo S; Alabdulrahman M; McGrath J; Dowling GP; AlRawashdeh MM; Hill ADK; Varešlija D; Young L
Curr Oncol Rep; 2024 Jun; ():. PubMed ID: 38822929
[TBL] [Abstract][Full Text] [Related]
47. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
48. Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
Sztupinszki Z; Diossy M; Borcsok J; Prosz A; Cornelius N; Kjeldsen MK; Mirza MR; Szallasi Z
Clin Cancer Res; 2021 Oct; 27(20):5681-5687. PubMed ID: 34380641
[TBL] [Abstract][Full Text] [Related]
49. A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures.
Diossy M; Sztupinszki Z; Borcsok J; Krzystanek M; Tisza V; Spisak S; Rusz O; Timar J; Csabai I; Fillinger J; Moldvay J; Pedersen AG; Szuts D; Szallasi Z
NPJ Precis Oncol; 2021 Jun; 5(1):55. PubMed ID: 34145376
[TBL] [Abstract][Full Text] [Related]
50. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
51. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers.
Farmanbar A; Firouzi S; Kneller R; Khiabanian H
J Transl Med; 2022 Feb; 20(1):65. PubMed ID: 35109853
[TBL] [Abstract][Full Text] [Related]
52. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
[TBL] [Abstract][Full Text] [Related]
53. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
[TBL] [Abstract][Full Text] [Related]
54. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
Llop-Guevara A; Loibl S; Villacampa G; Vladimirova V; Schneeweiss A; Karn T; Zahm DM; Herencia-Ropero A; Jank P; van Mackelenbergh M; Fasching PA; Marmé F; Stickeler E; Schem C; Dienstmann R; Florian S; Nekljudova V; Balmaña J; Hahnen E; Denkert C; Serra V
Ann Oncol; 2021 Dec; 32(12):1590-1596. PubMed ID: 34520831
[TBL] [Abstract][Full Text] [Related]
55. Impact of homologous recombination deficiency biomarkers on outcomes in patients with early breast cancer: a systematic review protocol.
Liao H; Pei W; Zhong J; Li H
BMJ Open; 2022 Aug; 12(8):e059538. PubMed ID: 35981778
[TBL] [Abstract][Full Text] [Related]
56. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
[TBL] [Abstract][Full Text] [Related]
57. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
How JA; Jazaeri AA; Fellman B; Daniels MS; Penn S; Solimeno C; Yuan Y; Schmeler K; Lanchbury JS; Timms K; Lu KH; Yates MS
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668244
[TBL] [Abstract][Full Text] [Related]
58. Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
Min A; Kim K; Jeong K; Choi S; Kim S; Suh KJ; Lee KH; Kim S; Im SA
Sci Rep; 2020 Jul; 10(1):12506. PubMed ID: 32719318
[TBL] [Abstract][Full Text] [Related]
59. Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
Lai Z; Brosnan M; Sokol ES; Xie M; Dry JR; Harrington EA; Barrett JC; Hodgson D
BMC Cancer; 2022 Jan; 22(1):13. PubMed ID: 34979999
[TBL] [Abstract][Full Text] [Related]
60. Case Report Series: Aggressive HR Deficient Colorectal Cancers Related to BRCA1 Pathogenic Germline Variants.
Freire MV; Martin M; Thissen R; Van Marcke C; Segers K; Sépulchre E; Leroi N; Lété C; Fasquelle C; Radermacher J; Gokburun Y; Collignon J; Sacré A; Josse C; Palmeira L; Bours V
Front Oncol; 2022; 12():835581. PubMed ID: 35280729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
